Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Current Assets (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Current Assets data on record, last reported at $296.6 million in Q3 2025.

  • For Q3 2025, Current Assets fell 24.67% year-over-year to $296.6 million; the TTM value through Sep 2025 reached $296.6 million, down 24.67%, while the annual FY2024 figure was $355.9 million, 495.15% up from the prior year.
  • Current Assets reached $296.6 million in Q3 2025 per ZBIO's latest filing, up from $278.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $393.8 million in Q3 2024 and bottomed at $59.8 million in Q4 2023.
  • Average Current Assets over 3 years is $283.8 million, with a median of $307.2 million recorded in 2025.
  • Peak YoY movement for Current Assets: skyrocketed 495.15% in 2024, then fell 24.67% in 2025.
  • A 3-year view of Current Assets shows it stood at $59.8 million in 2023, then surged by 495.15% to $355.9 million in 2024, then dropped by 16.66% to $296.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $296.6 million in Q3 2025, $278.6 million in Q2 2025, and $317.8 million in Q1 2025.